214 related articles for article (PubMed ID: 32920359)
41. Ginsenoside metabolite compound K induces apoptosis and autophagy in non-small cell lung cancer cells via AMPK-mTOR and JNK pathways.
Li C; Dong Y; Wang L; Xu G; Yang Q; Tang X; Qiao Y; Cong Z
Biochem Cell Biol; 2019 Aug; 97(4):406-414. PubMed ID: 30475650
[TBL] [Abstract][Full Text] [Related]
42. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
[TBL] [Abstract][Full Text] [Related]
43. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
[TBL] [Abstract][Full Text] [Related]
44. Potent inhibition of gastric cancer cells by a natural compound via inhibiting TrxR1 activity and activating ROS-mediated p38 MAPK pathway.
He W; Cao P; Xia Y; Hong L; Zhang T; Shen X; Zheng P; Shen H; Zhao Y; Zou P
Free Radic Res; 2019 Jan; 53(1):104-114. PubMed ID: 30668191
[TBL] [Abstract][Full Text] [Related]
45. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
46. Identification of osimertinib (AZD9291) as a lysine specific demethylase 1 inhibitor.
Li ZR; Suo FZ; Hu B; Guo YJ; Fu DJ; Yu B; Zheng YC; Liu HM
Bioorg Chem; 2019 Mar; 84():164-169. PubMed ID: 30502627
[TBL] [Abstract][Full Text] [Related]
47. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
[TBL] [Abstract][Full Text] [Related]
48. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer.
Kao SJ; Lee WJ; Chang JH; Chow JM; Chung CL; Hung WY; Chien MH
Environ Toxicol; 2017 Apr; 32(4):1426-1438. PubMed ID: 27539140
[TBL] [Abstract][Full Text] [Related]
49. Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Loprevite M; Favoni RE; de Cupis A; Pirani P; Merlo F; Grossi F; Ardizzoni A
Int J Oncol; 1999 Oct; 15(4):787-92. PubMed ID: 10493963
[TBL] [Abstract][Full Text] [Related]
50. Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway.
Wang WJ; Mao LF; Lai HL; Wang YW; Jiang ZB; Li W; Huang JM; Xie YJ; Xu C; Liu P; Li YM; Leung ELH; Yao XJ
Pharmacol Res; 2020 Nov; 161():105129. PubMed ID: 32783976
[TBL] [Abstract][Full Text] [Related]
51. Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/JNK and potentiates cisplatin efficacy in gastric cancer treatment.
Jiang XY; Zhu XS; Xu HY; Zhao ZX; Li SY; Li SZ; Cai JH; Cao JM
Acta Pharmacol Sin; 2017 Jul; 38(7):1048-1058. PubMed ID: 28344324
[TBL] [Abstract][Full Text] [Related]
52. Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition.
Chen X; Wu Q; Chen Y; Zhang J; Li H; Yang Z; Yang Y; Deng Y; Zhang L; Liu B
Br J Pharmacol; 2019 Jun; 176(12):2079-2094. PubMed ID: 30825187
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
54. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
[TBL] [Abstract][Full Text] [Related]
55. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
[TBL] [Abstract][Full Text] [Related]
56. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
58. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.
Lang DS; Droemann D; Schultz H; Branscheid D; Martin C; Ressmeyer AR; Zabel P; Vollmer E; Goldmann T
Respir Res; 2007 Jun; 8(1):43. PubMed ID: 17567922
[TBL] [Abstract][Full Text] [Related]
59. LukS-PV induces cell cycle arrest and apoptosis through p38/ERK MAPK signaling pathway in NSCLC cells.
Qiang Y; Ma F; Wang Z; Nie Z; Xu L; Ding P; Ma X
Biochem Biophys Res Commun; 2020 Jan; 521(4):846-852. PubMed ID: 31708104
[TBL] [Abstract][Full Text] [Related]
60. Exopolysaccharide from Cryptococcus heimaeyensis S20 induces autophagic cell death in non-small cell lung cancer cells via ROS/p38 and ROS/ERK signalling.
Hao Y; Huang Y; Chen J; Li J; Yuan Y; Wang M; Han L; Xin X; Wang H; Lin D; Peng F; Yu F; Zheng C; Shen C
Cell Prolif; 2020 Aug; 53(8):e12869. PubMed ID: 32597573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
